However, CD38 receptor block resulted in down-modulation of CD43 in both CLL and Th cells, which was coupled to a selective reduction of surface galectin-1, which may account for the specific inhibition of proliferating CLL cells while leaving Th cells unaffected. The gene discussed is LGALS1; the disease is B-cell chronic lymphocytic leukemia.